Objective: The LH/chorionic gonadotrophin receptor (LHCGR) is a G protein-coupled receptor (GPCR) that plays a central role in male sexual differentiation, regulation of ovarian follicular maturation, ovulation and maintenance of corpus luteum and pregnancy, as well as maintenance of testicular testosterone production. Mutations in the LHCGR gene are very rare. The aim of this work was to study the clinical and molecular characteristics of a rare familial LHCGR mutation. Methods: Five affected members of a family, including a phenotypically female, but genotypically male (46,XY), patient with Leydig cell hypoplasia type 1 and four genotypically female siblings with reproductive abnormalities, were studied genetically. Cell trafficking studies as well as signalling studies of mutated receptor were performed. Results: The five affected patients were all homozygous for a novel mutation in the LHCGR gene, a deletion of guanine in position 1850 (1850delG). This resulted in a frameshift affecting most of the C-terminal intracellular domain. In vitro studies demonstrated that the 1850delG receptor was completely incapable of transit to the cell membrane, becoming trapped within the endoplasmic reticulum. This could not be rescued by small-molecule agonist treatment or stimulated intracellularly by co-expression of a yoked human chorionic gonadotrophin. Conclusions: This novel LHCGR mutation leads to complete inactivation of the LHCGR receptor due to trafficking and signalling abnormalities, which improves our understanding of the impact of the affected structural domain on receptor trafficking and function.
Introduction
In humans, the luteinizing hormone/chorionic gonadotrophin receptor (LHCGR) transduces intracellular signalling upon activation by either of its ligands: LH or human chorionic gonadotrophin (hCG), secreted by the pituitary gland and placenta respectively. In men, theproduction by fetal and adult Leydig cells, thereby promoting the differentiation and maturation of the male extragonadal phenotype in response to hCG during embryogenesis and later in response to post-natal LH secretion.
The importance of the LHCGR in male phenotypic development is well known, as individuals carrying partially inactivating mutations of the LHCGR present with hypogonadal phenotypes of variable severity, ranging from micropenis to hypospadias (Leydig cell hypoplasia type 2 (LCHT2)). Karyotypic males carrying completely inactivating LHCGR gene mutations have a disorder of sexual differentiation (DSD) comprising the complete absence of male differentiation (i.e. they have female external genitalia) due to absent androgenisation during fetal development (termed Leydig cell hypoplasia type 1 (LCHT1)) (1) . In women, inactivating LHCGR mutations do not affect the early normal development of primary and secondary sexual characteristics, but they cause primary or secondary amenorrhoea and infertility due predominantly to a lack of pre-ovulatory follicular maturation and ovulation (2, 3) . Probably, due to their profound effect on fertility in both sexes, severe inactivating mutations of the LHCGR gene present very rarely in a clinical setting. Thorough analysis of rare mutations reveals important information regarding structurefunction relationships of the LHCGR and related G protein-coupled receptors (GPCRs).
Herein, we report a rare case of LCHT1 due to a novel mutation in the LHCGR gene that reveals significant functional consequences due to impaired receptor trafficking and signalling.
Patient and methods

Case report
A 35-year-old North African patient was referred to the gynaecological unit for primary amenorrhoea. She was the fourth child of the kindred comprising eight members (7F, 1M), and consanguinity was present as her parents were first cousins. Two sisters had apparently normal secondary sexual development: one had four offspring, while the other sister, although she had no children, had normal pubertal development and regular menstruation. The brother was in good health and had three healthy children. The other four sisters all presented with reproductive system abnormalities: three had primary amenorrhoea and variable breast development, while one had irregular menstrual cycles and normal breast development. All four had a normal female karyotype 46,XX. Further detailed gynaecological and endocrine investigations were declined.
On examination, the patient had a eunuchoid habitus, pre-pubertal breast development (B1), and scant axillary and pubic hair (P2). Acne and hirsutism were absent and body weight was normal. On gynaecological examination, normal female external genitalia were present, the vagina was blindended and no pelvic masses were palpable.
Biochemistry results found very low levels of oestradiol (!20 pg/ml, postmenopausal value) and testosterone (!0.03 ng/ml; normal range (NR): 0.06-0.86) with high LH (22.70 mU/l; NR: 1.3-10.1) and normal FSH levels (12 mU/l; NR: 1.4-13.6). Thyroid hormones, prolactin, cortisol and DHEA-S levels were within normal ranges. Marked osteoporosis was found on DEXA (T-score: K3.99 (trabecular); K3.16 (cortical)) with a stress fracture in the left ankle. Abdomino-pelvic ultrasound and MRI revealed absent uterus and other Müllerian structures. Apart from the small vaginal cavity (3.0!5.0 cm), bilateral masses (2.0!1.5!1.0 cm) in the superior inguinal canal were found, consistent with testicular remnants. The karyotype was 46,XY.
The patient underwent bilateral gonadectomy; histology confirmed testicular tissue comprising immature seminiferous tubules with a thickened basement membrane and no lumen (Fig. 1A) , fibroblast-like interstitial cells and epididymal structures in the tissue adjacent to the gonad. Immunohistochemistry staining with anti-inhibin-a (CMC28340021, Cell Marque Corporation, Rocklin, CA, USA) and anti-3bhydroxysteroid dehydrogenase (anti-3bHSD) (sc-30820, 1:200, Santa Cruz Biotechnology, Inc.) antibodies was performed in the patient tissue and in normal testicular tissue to illustrate the presence of Leydig cells. Immunohistochemistry staining with anti-placental alkaline phosphatase (anti-PLAP) antibodies (CMC26640021, Cell Marque Corporation), a marker of germ cells, was also performed.
Mutation detection
Following counselling, the patient consented to genetic studies. DNA was extracted from peripheral blood leukocytes by phenol-chloroform extraction. The LHCGR coding sequence was amplified by PCR followed by direct sequencing of PCR products. Exons 1-11 were amplified by one touchdown PCR. The PCR products were purified with ExoSAP-IT (USB Corporation, Cleveland, OH, USA) according to the manufacturer's instructions and then sequenced with the BigDye Terminator Ready Reaction Mix v.1.1 (Applied Biosystems). The four sisters with menstrual anomalies also underwent counselling and genetic sequencing of the LHCGR gene.
Construction of mutant cDNA expression vectors
The HA-tagged WT human LHCGR cDNA cloned into the pSG5 vector (4) was mutated as described elsewhere (manuscript in preparation). Briefly, PCR was performed using KOD Xtreme polymerase (Millipore, Espoo, Finland) with the primers described in Supplementary Table S1, see section on supplementary data given at the end of this article and then digested with DpnI to remove the template plasmid. The linear PCR product was joined by recombineering (see Supplementary material for full sequences as well as Supplementary Figures S1 and S2) .
Two positive clones carrying the mutated LHCGR sequence and two WT clones underwent sequencing to verify the normal and mutated sequences, the latter being referred to henceforth as HA-1850delG. These two clones for each WT and mutant were used for all downstream procedures. They were then amplified in Escherichia coli and purified using a maxiprep kit (Macherey-Nagel, Düren, Germany). The purified plasmids were used for transfection of HEK293-GS cells (see below) using JetPEI (Polyplus, Illkirch, France).
Signal transduction
The HEK293 cells used in this study have been stably transfected with a sensor plasmid for cAMP (GloSensor-22F, Promega). This cell line, hereafter referred to as HEK293-GS cells, was cloned for its sensitivity and stability in the detection of cAMP generated by forskolin (Sigma) treatment as reported previously (5) .
HEK293-GS cells in 24-well plates were transfected with either the WT HA-LHCGR or the HA-1850delG plasmids. Transfected HEK293-GS cells were incubated for 48 h in normal medium (DMEM-F12 conditioned with 10% FCS) before the analysis of cAMP generation.
Cells were then analysed for their responsiveness to recombinant human LH (rhLH) or hCG, 50 nM, in 50% DMEM/50% CO 2 -independent medium (Invitrogen) and 2% GloSensor reagent (Promega). The generation of cAMP directly correlates with the activation of the GloSensor luciferase reporter system. Luminescence was recorded in a Victor plate reader (Wallac, Turku, Finland) at intervals of 10 s for over 60 min (kinetic measurements). The recorded values were presented as luminescence per second.
Trafficking studies
To detect whether the mutant receptor localises to the cell membrane, we used a standard flow cytometry protocol, where, in non-permeabilised cells, the detection of the receptor can only be achieved if the receptor is expressed on the cell membrane, while, in permeabilised cells, the presence of the receptor will be detected by the antibody as to whether it is on the cell membrane or located intracellular (6) . HEK293-GS cells transfected with either HA-WT or HA-1850delG LHCGR plasmids were then incubated with a primary antibody (goat anti-HA; Bethyl, Helsinki, Finland) against the HA tag, for 30 min. The medium was removed and the cells were washed twice with 
Intracellular activation and rescuing of the mutant LHCGR
The yoked hCG (yhCG), a fusion of both hCG subunits that forms an active hCG molecule (kindly provided by Prema Narayan (7)), was co-transfected with the LHCGRs (mutant and WT) to HEK293-GS cells as described earlier in this report. Then, 48 h after transfection, cAMP generation was measured as described earlier in this report without further addition of ligand. The HEK293-GS cells were transfected with either the WT LHCGR or the 1850delG plasmids and were incubated for 24 h in the presence of the allosteric LHCGR agonist, Org 42599 (kindly provided by Dr Claire Newton (8)), and cAMP generation was measured before (agonist overnight (ON)) or after addition of ligand (100 ng of recombinant human CG (rhCG)).
Endoplasmic reticulum stress assay
Endoplasmic reticulum (ER) stress was determined by the transcriptional activity of the ER stress element (ERSE), detected by the Cignal ERSE Reporter Luciferase Assay (SA Bioscience Qiagen). The ERSE reporter assay is based on a mixture of an ERSE-responsive firefly luciferase construct and a constitutively expressed Renilla luciferase construct -as a transfection control. Luciferase activities were measured using the Dual Luciferase assay kit (Promega) using a plate reader (EnSight, PerkinElmer, Turku, Finland), and the results are expressed as a ratio of the ERSE firefly luciferase reporter to Renilla luciferase. HEK293 cells were transfected in 96-well plates with a negative control (pcDNA), or a positive control, or an ERSE reporter plus either the WT LHCGR or the 1850delG-LHCGR for 48 h before analysis. Every condition was performed in triplicate and the assays were performed at least twice. Data are expressed as meanGS.D. (nZ3).
Results
Immunohistochemistry staining
Immunohistochemistry staining with anti-inhibin-a and anti-3bHSD antibodies showed the absence of Leydig cells ( Fig. 1C and E) compared with normal testicular tissue ( Fig. 1D and F) . Germ cells were also absent on immunohistochemistry staining with anti-PLAP antibodies (Fig. 1B) .
Mutation detection
Sequencing of the LHCGR gene revealed deletion of a guanine at position 1850. This deletion led to a frameshift mutation where the original C-terminal 83 coded amino acids are replaced by 21 new amino acids (starting from p.Cys617Leu) followed by a termination codon (Supplementary Figure S2 and Supporting material). The patient and the four 46,XX sisters with menstrual anomalies were homozygous for the mutation.
We recreated an identical mutant (1850delG) by modifying a HA-tagged LHCGR cDNA cloned into a mammalian expression vector (pSG5). The site-directed deletion was verified by sequencing (Supporting material). The addition of the HA-tag is important for expression and localisation analyses. The amino acid changes in the 1850delG when compared with the WT LHCGR as well as a schematic representation of the changes in the C-terminal of the mutant receptor ( Figure S2 ) when compared with the WT receptor (Supplementary Figure S1) are described in the Supplementary Material. tested concentrations of rhLH or rhCG, unlike those expressing the WT receptor (Fig. 2) . This lack of signal transduction corresponds well to the patient's phenotype of severely impaired testosterone production.
In order to study the effects of the mutation on receptor localisation, trafficking and signalling, we tested the presence of the mutant receptor at the cell membrane using an antibody against the extracellular N-terminal HA-tag, analysed by flow cytometry and immunocytochemistry. While the WT HA-LHCGR was detected on the cell membrane of transfected cells, the HA-1850delG mutant was completely absent from the cell membrane (Fig. 3 top row and Fig. 4 first and second rows) , but could be detected in permeabilised cells (Fig. 3 bottom row and Fig. 4 third and fourth rows) , which showed that the receptor was normally expressed, but its trafficking to the cell membrane was compromised.
The accumulation of misfolded proteins in the ER causes the ER stress response that is a cellular process triggered in order to protect the cells from further stress injury (reviewed in (9)). Indeed, transfection with the 1850delG mutant resulted in more than twice the ER-stress caused by transfection of either the WT counterpart or an empty plasmid (pcDNA) (Fig. 5C) .
We attempted to activate the receptors at the ER by co-expressing a yhCG, a fusion of both hCG subunits that forms an active hCG molecule (7). We hypothesised that, 
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Cells expressing the mutant receptor did not produce increased cAMP after overnight incubation with the allosteric LHCGR agonist, Org 42599, either alone or in combination with hCG. In contrast, cells expressing the WT LHCGR responded to both with increased cAMP generation (Fig. 5B) .
Discussion
We present a case of a family with a newly described inactivating mutation of the LHCGR gene. It reveals a novel deletion of nucleotide 1850G, leading to a frameshift alteration of amino acids 617-637 (situated in the 7th transmembrane domain (TM7)) and a premature stop codon. This modifies the receptor's C-terminal sequence from that of the WT receptor, by replacing the last 83 amino acids, including all of the intracellular tail, by an incorrect and truncated 21-amino acid sequence.
Several mutations hampering LHCGR function have been described to date. The phenotype depends on the underlying sex of the patient and also on the degree of receptor inactivation caused by the mutation. At the severe end of the spectrum are exceptionally rare cases of inactivating mutations of LHCGR, which result in a nearcomplete lack of masculine development and pseudohermaphroditism, classified as LCHT1, as in the propositus of this family. In the case of partially inactivating LHCGR mutations or mutants that are poorly sensitive to LH but responsive to hCG (10), genotypic (46,XY) males can have a spectrum of disorders from micropenis to hypospadias (1). These can share some similarity to mutants of the LH beta subunit (LHB) (11, 12, 13, 14, 15) and all are categorised as LCHT2. The reason for such normal prenatal but abnormal postnatal phenotype is due to the role played by placental hCG during fetal development in primates, including humans. The phenotype of the affected female siblings who were also homozygous for 
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www.eje-online.org the LHCGR mutation echoes that of previously described cases, having either amenorrhoea or oligomenorrhoea plus variable breast development. The patient described herein belongs to the LCHT1 category, with an immature female phenotype despite the 46,XY karyotype. To date, 17 LHCGR mutation families leading to disorders of male sex development (with phenotypic female appearance) have been described. These mutations were due to different mechanisms: substitutions, small or large deletions and insertions (16) .
The clinical presentation of the propositus is similar to other reported cases: eunuchoid habitus, the absence of secondary sex characteristics and the presence of intraabdominal testes. The testicular pathology is explained by the androgen-independent differentiation of the primordial gonad in males by expression of the SRY gene located on the Y chromosome. Thereafter, the primordial gonad acquires a tubular structure with Sertoli cells beginning to secrete anti-Müllerian hormone. It is this hormone that signals the regression of the Müllerian ducts, the derivatives of which would otherwise form part of the female internal reproductive system. However, after this initial stage, testicular differentiation and development are dependent on testosterone secretion by the Leydig cells. The fetal Leydig cells begin steroidogenesis in a gonadotrophin-independent manner, leading to development of the vas deferens and epididymis from the Wolffian duct. This process is achieved even under low androgen receptor (AR) stimulation, as in patients with complete androgen insensitivity syndrome (CAIS) but residual AR activity, who have remnants of epididymis and vas deferens (17) . Similar to cases of CAIS, in our patient, germ cells were absent on histological examination. This is most probably due, on one hand, to the limited AR stimulation. In a recent study, Kaprova-Pleskacova et al. (18) found that survival of germ cells in CAIS patients was significantly related to the residual AR activity. On the other hand, germ cell numbers in CAIS patients decrease with age, with a rapid decline after the first year of life (19) .
Animal models of inactivating LHCGR mutations (20, 21) exhibit a different phenotype from that of the human, which is understandable given the lack of CG in non-primates apart from equines (22, 23) . At birth, male mice with homozygous inactivating mutations of the Lhcgr have the same phenotype as their WT littermates. It is only postnatally that a low testosterone secretion and impaired reproductive tract development set apart the former from the latter. An LH/LHCGR-independent alternative mechanism for embryonic testosterone generation is present in rodents (24) and a basal level of testosterone is generated in Lhcgr-knockout mice (LuRKO) resulting in incomplete spermatogenesis at 12 months of age (25) .
At the molecular level, the mutation described herein seems to present a particularly severe phenotype. Despite being expressed, albeit at lower levels than the WT, the mutant LHCGR is incapable of signal transduction as it is unable to reach the cell membrane. Sequestered, misfolded proteins in the ER trigger the unfolded protein response (UPR) and reduce gene expression (26) , which may well explain the molecular pathogenesis of this 1850delG mutant. A point mutant of the LHCGR A593P, leading to a phenotype of male DSD (27) , and S616Y, leading to LCHT2 (28) , are also retained in the ER, but both can be rescued by the allosteric LH receptor agonist Org 42599 (8) , which induced surface expression of these receptors and further led to signal transduction (8) . In marked contrast, in our case, overnight incubation with the pharmacological chaperone alone or in combination with hCG had no effect on cAMP production, probably due to the severe alteration of the amino acid sequence, which prevents the possibility of correct tertiary structure folding.
The LHCGR is a member of GPCR class A (29) . Export from the ER to the cell membrane is the last event in intracellular trafficking of GPCRs and it is a highly regulated event where quality-control mechanisms ensure that receptors are properly folded and glycosylated before further processing (reviewed in (30) ). The structural determinants for this trafficking event in GPCRs often have led to changes in a common motif located towards the cytoplasmic end of the TM7, NPxxY, part of the larger conserved NSxxNPxxY sequence (29) . The NPxxY motif of GPCRs seems to introduce, due to the proline residue, a kink in the a-helix with a flexible 'hinge' region (31) , which is important in receptor activation (32) . Mutants in this region have also been reported for the LHCGR (33), although mutations elsewhere that retain the receptor at the ER also exist. Mutations located in TM domains or even in the extracellular regions of the LHCGR have been reported (34, 35) . However, in most of the cases mentioned, the mutant receptors had some degree of membrane expression, which is not the case for the 1850delG mutant. The large anomaly introduced by the 1850delG leads to the transcription of a protein that probably folds incorrectly, and the quality control mechanisms of the ER therefore trigger its retention and degradation.
Truncation of the rat LHCGR at residue 616 (human equivalent 637) with 11 residues left in the cytoplasmic tail, originally of 69 residues, leads to impaired receptor expression on the cell membrane, which is not the case for truncations further downstream at residues 631 (human equivalent 652) or 653 (human equivalent 674) (33) . The reduced expression could be due to the fact that the two cysteine residues 621 and 622 (human equivalents 643 and 644) are eliminated in the 616 truncation. These palmitoylated residues seem to be involved in receptor localisation, as well as ligand-bound maintenance on the cell membrane (36, 37) .
Numerous mutagenesis studies have been performed on the conserved NSxxNPxxY domain of various GPCRs showing that this domain is also important for signal transduction (G protein activation), ligand binding and receptor post-signalling sequestration (38, 39, 40) . The alteration found in our case begins two amino acids before the NPxxY motif and completely modifies its structure (Supporting material Figures S1 and S2 , see section on supplementary data given at the end of this article) in a manner that leads to a signalling deficiency, as none of the rescuing experiments resulted in 1850delG receptor stimulation.
LHCGR-1850delG is a novel frameshift mutant reported in this receptor. The resulting phenotype and molecular analyses are in agreement that this receptor is completely inactive. The receptor is unable to transit to the cell membrane, thus unable to contact with its ligands (LH or hCG) and most likely incapable of signalling, resulting in the LCHT1 phenotype.
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